| Literature DB >> 30596697 |
Bethany Powell1,2, Igal Szleifer1,3,4, Yasin Y Dhaher5,6.
Abstract
Following an anterior cruciate ligament injury, premenopausal females tend to experience poorer outcomes than males, and sex hormones are thought to contribute to the disparity. Evidence seems to suggest that the sex hormones estrogen, progesterone, and testosterone may regulate the inflammation caused by macrophages, which invade the knee after an injury. While the individual effects of hormones on macrophage inflammation have been studied in vitro, their combined effects on post-injury inflammation in the knee have not been examined, even though both males and females have detectable levels of both estrogen and testosterone. In the present work, we developed an in silico kinetic model of the post-injury inflammatory response in the human knee joint and the hormonal influences that may shape that response. Our results indicate that post-injury, sex hormone concentrations observed in females may lead to a more pro-inflammatory, catabolic environment, while the sex hormone concentrations observed in males may lead to a more anti-inflammatory environment. These findings suggest that the female hormonal milieu may lead to increased catabolism, potentially worsening post-injury damage to the cartilage for females compared to males. The model developed herein may inform future in vitro and in vivo studies that seek to uncover the origins of sex differences in outcomes and may ultimately serve as a starting point for developing targeted therapies to prevent or reduce the cartilage damage that results from post-injury inflammation, particularly for females.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30596697 PMCID: PMC6312367 DOI: 10.1371/journal.pone.0209582
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1A. Depiction of monocyte and macrophage migration and transformation. Injury to the knee causes the production of chemoattractants, such as TNF-α and TGF-β, which lead to monocyte migration from the bloodstream to the synovium. The synovium is indicated by the gray dashed box. Monocytes transform into pro-inflammatory M1 macrophages. The molecular processes that drive transformation to M1 cells are not modeled. Instead, a 12-hour delay is incorporated into the model as a way to account for the time it takes for monocytes to transform, as previously described [19]. IL-10 drives the transformation of M1 cells to anti-inflammatory M2 macrophages [21]. Both M1 and M2 cells can migrate out of the synovium. B. Cellular production and feedback regulation of a subset of the substances incorporated in the model. M1 and SF both produce IL-10, IL-1, IL-6, and MMP-1. IL-10 down-regulates M1 production of IL-1 and IL-6, while IL-1 up-regulates SF production of IL-1, IL-6, and MMP-1. IL-6 up-regulates M1 IL-10 and up-regulates M1 IL-1. Estrogen (E) up-regulates M1 production of IL-1 and down-regulates M1 production of IL-10 and IL-6, while testosterone (T) up-regulates M1 production of IL-10. Progesterone (P) down-regulates M1 IL-6. M1: pro-inflammatory macrophage. M2: anti-inflammatory macrophage. SF: synovial fibroblast. E: estrogen. T: testosterone.
Equations for cellular migration.
| Model Variable | Initial Value | Concentration in Healthy Synovium | Equation |
|---|---|---|---|
| “Platelets” | |||
| M1 Macrophages | |||
| M2 Macrophages | |||
| SFs |
Formulations of f and f, and the values of their parameters can be found in S2 Table.
Equations for cellular products.
| Model Variable | Initial Value (from Model Steady State) | Concentration in Healthy Synovium | Ref. | Equation |
|---|---|---|---|---|
| IL-1β | [ | |||
| TNF-α | [ | |||
| IL-6 | [ | |||
| IL-10 | [ | |||
| TGF-β | [ | |||
| TIMP-1 | [ | |||
| MMP-9 | [ | |||
| MMP-1 | [ |
* In some cases, the margin of error for the measurements extended below a concentration of 0 pg/mL, suggesting that the experimental data may have been non-normally distributed, may have had extreme outliers, or may have been averaged over a small number of samples. However, very few studies report concentrations of cytokines in healthy joints, and the ones cited here serve as an adequate starting point for comparisons.
** Our estimate of initial MMP-9 concentration is lower than the concentration reported in a healthy knee. However, this will lead to a conservative estimate of its concentration once an inflammatory stimulus is included in the model.
*** Our estimate of TGF-β exceeds the concentration in a healthy joint. However, its initial value in the model is only about 1% of its peak value, so we argue that its effect will be minimal.
Fig 2Summary of model formulation process.
A. Estimation of Nominal Parameter Values. The first step in the modeling process was to estimate the nominal production and decay rate coefficients (see section 2.1) from N = 23 published in vitro studies (cited in S1 Table). B. Parametric Variations. We varied these parameters between 40% and 160% (±60%) of their nominal values, generating a 2000 element row vector associated with every parameter. The values in these row vectors were evenly spaced and sorted in ascending order. C. Parameter Matrix [P]. Next, we randomized the order of each individual row vector before stacking the vectors into a Γ by 2000 matrix, [P], where Γ represented the number of nominal parameters (and, therefore, the number of row vectors) in the model. Because of the randomization and stacking, each individual column in [P] represented a randomly varied parameter set that we could use in the differential equations. D. Latin Hypercube Sampling Process. We selected column i from [P] to generate the ith parameter set and solved the differential equations. After solving the equations with all 2000 randomly varied parameter sets, we determined the median and interquartile range of the results at every time point for every substance, generating the likelihood time responses for concentration under parametric uncertainties. This parametric uncertainty analysis helped us account for uncertainties in the in vitro experiments that we used to estimate the nominal values, such as varied experimental conditions and limited numbers of samples. Furthermore, this analysis helped us account for biological differences that exist between the in vitro experiments from which we formulated the parameters and the in vivo states that we sought to model.
Estrogen and testosterone ranges for males and females.
These concentrations were obtained from Greenspan et al. (2004) [38].
| Minimum E (pM) | Maximum E (pM) | Minimum T (nM) | Maximum T (nM) | |
|---|---|---|---|---|
| Male | 1.0 | 106 | 8.7 | 38.1 |
| Female Low E | 143 | 673 | 0.069 | 1.38 |
| Female Peak E | 2266 | 2797 | 0.069 | 1.38 |
Fig 3Model results for latin hypercube sampling analysis of IL-1β, TNF-α, and IL-10 compared to independent in vivo synovial concentrations following anterior cruciate ligament (ACL) injury [37].
Simulation results shown as median (solid gray lines) ± IQR (gray bands). In vivo comparison data are shown as circles with error bars. See S1 Fig and S4 Table for independent comparisons of the rest of the substances in the model.
Fig 4Using the nominal parameter set, sex hormones modulate post-injury IL-1β, TNF-α, and IL-10.
E Only: low estrogen concentration, as for the early follicular phase (143 pM); E + P: low levels of estrogen and progesterone, as for the early follicular phase (143 pM estrogen, 990 pM progesterone); T Only: testosterone concentration in the normal range for an adult male (20 nM).
Fig 5Effects of combined estrogen and testosterone at physiological levels for males and females (median ± IQR).
Blue: combined T and E at concentrations for adult males; red solid: females with combined T and E at concentrations for females in the early follicular phase (Female Low E); green dotted: combined T and E for females with a steady estrogen concentration that varies around the peak value of estrogen during the menstrual cycle (Female Peak E). Kruskal-Wallis testing and post hoc Mann-Whitney U testing (with the Bonferroni correction) reveal highly significant differences between hormonal conditions at nearly all time points for all substances (analysis included in S1 Scripts). For IL-1β, IL-10, and MMP-1, there are significant differences between every possible hormone pair: “Male” is significantly different from “Female Peak E;” “Male” is significantly different from “Female Low E;” and “Female Peak E” is significantly different from “Female Low E.” The difference in MMP-1 concentration between “Male” and “Female Low E” lose significance at t = 19 days and t = 20 days. TNF-α is the only exception, as it shows no significant differences between “Female Low E” and “Female Peak E” at any time point. Further, no differences exist between hormone conditions t = 0 days, since the initial conditions are the same, regardless of the hormone treatment.